case_images: PMC5292363_01
case_images: Computed tomography scan of the patient of case 1 at the diagnosis of metachronous hepatic and pulmonary metastases.
case_images: CRIONM2017-6139634.001.jpg
case_images: PMC5292363_01_CRIONM2017-6139634.001.jpg
case_images: fig1
case_images: II (pT3, N0 (0/16), L0, M0 and R0), and, accordingly, no adjuvant therapy was given. In 2014, he presented again with hepatic and pulmonary metastases (Figure 1).
case_images: PMC5292363_02
case_images: Dynamics of a KRAS mutant clone in plasma samples of the patient in case 2. The red line indicates the frequency of KRAS exon 3 mutation (percentage of alleles) detected in circulating DNA at the indicated time points. Progressive disease occurred after the long-term treatment with anti-EGFR antibodies. After interruption of anti-EGFR therapy; the KRAS mutation load distinctly declined and remained below the limit of detection across subsequent lines of treatment. "E" represents therapy with anti-EGFR antibodies and chemotherapy and "V" therapy with anti-VEGF antibodies and chemotherapy; "PHE" acts for partial hepatectomy and "m" for month. Results of follow-up are indicated below the graphs: green box, partial remission; yellow box, stable disease; and red box, progressive disease.
case_images: CRIONM2017-6139634.002.jpg
case_images: PMC5292363_02_CRIONM2017-6139634.002.jpg
case_images: fig2
case_images: During this period, no RAS mutation was detectable by liquid biopsy (Figure 2).